top of page
Search
  • Opus Materia

Low Risk of Hyperprogression with First-LineChemoimmunotherapy for Advanced Non-Small Cell Lung Canc

Low Risk of Hyperprogression with First-Line

Chemoimmunotherapy for Advanced Non-Small Cell

Lung Cancer: Pooled Analysis of 7 Clinical Trials


Lee X. Li, Federico Cappuzzo, Ignacio Matos, Mark A. Socinski,

Ashley M. Hopkins, Michael J. Sorich


To read the article follow the link below:


LOW RISK OF HYPERPROGRESSION WITH FIRST LINE CHEMOIMMUNOTHERAPY FOR ADVANCED NSCLC
.pdf
Download PDF • 492KB

1 view0 comments

Comments


T.: 210 9423677   info@opusmateria.gr

bottom of page